MannKind Corporation - Common Stock (MNKD)

MannKind Corp. (NASDAQ: MNKD) reported strong Q4 and FY 2025 results, with earnings and sales beating expectations.

Mr. Market was hoping for a better fourth quarter than the company delivered.

United Therapeutics unveiled a new product called Tresmi, which is “a proprietary drug device formulation of treprostinil into a soft mist inhaler.”

The U.S. FDA approved an update to the prescribing information for Afrezza inhalation powder to treat adults with diabetes mellitus.

This biotech innovator in inhaled therapeutics reported a notable insider sale amid ongoing product development and licensing activity.

With shares battered and leverage rising, this quiet trim raises a sharper question about how much patience investors should have left.

The move suggests that shrinking margins, leadership turnover, and a shifting product mix are quietly reshaping the Lantheus investment case.

MannKind (MNKD) Q3 2025 results beat revenue and EPS estimates. The biopharma's shares rose on strong performance and strategic updates, including the scPharmaceuticals acquisition.

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

The deal hands MannKind access to scPharma’s Furoscix heart and kidney therapy, a product with a U.S. market potential estimated at over $10 billion.